Concord Biotech clears Kenya, Uganda drug inspections at Unit-II facility

Regulatory product approvalBusiness Updates View source PDF Explain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹1289.90

prior close

₹1298.50

announcement price

In-mkt

timing

Nifty Smallcap 250market-0.4%+0.1% vs market

Pharmaceuticals peers, median of 163sector-0.6%+0.2% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Smallcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.0

15m

-0.1

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4-0.4+0.1-0.6+0.2

Next day

-1.6-0.9-0.7-0.3-1.3

-0.5-0.4-0.1+0.5-0.9

-0.2+0.1-0.3+0.0-0.2

-0.4+1.1-1.5+0.3-0.6

-0.6+1.2-1.8+1.3-1.9

-1.5+0.9-2.5+0.1-1.6

15d

+3.8+1.2+2.6+0.8+3.0

-1.9+0.2-2.1+0.8-2.6

+20.2+3.2+17.1+1.2+19.1

+12.6+2.1+10.5+5.4+7.2

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Concord Biotech successfully completed inspections by Kenya's Pharmacy and Poisons Board (PPB) and Uganda's National Drug Authority (NDA) at its Unit-II formulation facility between June 18 and June 24, 2026. The clearance enables the company to supply pharmaceutical products in Kenya and Uganda and strengthens its global manufacturing and regulatory footprint in African markets.

Likely market impact

Opens African markets for Concord Biotech's formulations, supporting international revenue growth and validating quality standards for future regulatory approvals.